Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357188 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00357188 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants.
The verdict
NCT00357188, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects
Interventions
- DRUG Atazanavir Sulphate + Ritonavir
- DRUG Atazanavir Sulphate + Ritonavir + Efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00357188
The ClinicalTrials.gov registry entry for NCT00357188 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atazanavir Sulphate + Ritonavir is the first listed.
NCT00357188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00357188 about?
NCT00357188 is a clinical study titled "Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects". The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects
What is the current status of trial NCT00357188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-07. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00357188?
The interventions under investigation include: Atazanavir Sulphate + Ritonavir (DRUG), Atazanavir Sulphate + Ritonavir + Efavirenz (DRUG).
Who is sponsoring clinical trial NCT00357188?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.